Aromatic Compound Compositions for Metabolic and Liver Disease Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs for treating obesity-related conditions such as hyperlipidemia and type 2 diabetes have neutral effects on glycemic control or adverse side effects, and there is a need for compounds that can simultaneously target both hyperlipidemia and glycemic control without weight gain, while also addressing hepatic fibrosis and hepatic steatosis.
Innovation Solution
Development of aromatic compounds of formula (I) and their pharmaceutically acceptable salts, solvates, or prodrugs, which are used in pharmaceutical compositions to treat metabolic and liver diseases, including reducing plasma insulin levels, improving glucose tolerance, and reducing hepatic fibrosis and steatosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If drugs targeting glycemic control (e.g., insulin, thiazolidinediones) are used, then glycemic control is improved, but bodyweight increases and unwanted side effects occur
Solution Approach 1:
The patent modifies the chemical structure by changing parameters such as substituting aromatic rings with specific heterocyclic groups (e.g., pyrazolone, triazole), adjusting substituent positions, and varying alkyl chain lengths to optimize the balance between glycemic control efficacy and reduction of adverse effects like weight gain
Solution Approach 2:
The compounds combine multiple functional moieties within a single molecular structure, including aromatic rings, heterocyclic systems, and various substituents, to achieve multi-target activity that simultaneously improves glycemic control while minimizing unwanted side effects
2Measurement precision
If drugs treating hyperlipidemia (e.g., statins, fibrates) are used, then lipid levels are controlled, but glycemic control remains neutral and no benefit for hepatic fibrosis is achieved
Solution Approach 1:
The patent designs compounds with universal activity across multiple metabolic pathways and disease conditions, enabling single agents to simultaneously address hyperlipidemia, glycemic control, and hepatic fibrosis through mechanisms such as PPAR activation and FXR modulation
3Reliability
If current treatment approaches for metabolic diseases are used, then some conditions are managed, but hepatic fibrosis progression is not prevented and hepatic steatosis is not reversed
Solution Approach 1:
The patent employs compounds that act as molecular intermediaries or mediators, such as PPAR agonists and FXR modulators, which transmit therapeutic effects to multiple downstream targets including hepatic tissue, thereby preventing fibrosis progression and reversing steatosis while managing metabolic parameters
Data Source
AI summary
The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.